Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D and Cardiovascular Health: Mechanisms and Clinical Outcomes

Previous related pageFrom Endothelial Signals to Smooth-Muscle ToneNext related pageFrom Endothelial Signals to Smooth-Muscle Tone
At a glance

Do vitamin D supplements prevent heart attacks and strokes?

The two large trials discussed here do not establish a consistent overall benefit. The American trial found no clear reduction in major heart and circulation events. The Australian trial suggested a possible benefit, but its main result could also mean that vitamin D had no effect.

Why do vitamin D experiments in blood vessels matter?

They show how vitamin D signals could affect cells in blood vessels. A change in cell behaviour, vessel relaxation or a measure of inflammation does not by itself show that fewer people will have heart attacks or strokes.

Did the two trials of heart and circulation health test the same thing?

No. They used different schedules for taking vitamin D, groups of people and combinations of heart and circulation events. Their results cannot establish which schedule is better, or settle the effects of treating severe deficiency.

Read the full article below ↓

Vitamin D research reaches the cardiovascular system at several levels: receptors inside heart cells, the lining and muscle of blood vessels, circulating inflammatory markers, blood pressure and clinical events. These measurements do not answer the same question. This synthesis brings the Heart and Vascular Tone evidence together, then compares it with VITAL and D-Health, two large randomised trials that counted cardiovascular events.

Start with the outcome, then judge the claim

A biological mechanism explains how something could happen. A clinical trial asks whether a specified intervention changed a specified outcome in people. Neither makes the other unnecessary. The heart physiology overview provides the organ-level setting, while evidence hierarchies help match the research design to the question. The most useful reading rule is to keep the exposure, population and measurement attached to each result.

Evidence levelWhat it can showWhat remains a separate question
Heart-cell receptor experimentsChanges in cellular growth, cardiac structure or particular functional tests after genetic manipulationWhether nutritional supplementation prevents heart attacks or heart failure
Endothelial and muscle experimentsBarrier leakage, stimulated dilation, calcium-related signalling or contractile force in a defined preparationWhether all vascular functions or systemic pressure improve
Observational blood concentrationsAn association between measured vitamin D status and later eventsWhether low status caused the events or changing status prevents them
Randomised biomarkers or blood pressureThe effect of the assigned regimen on the measured marker or pressureWhether any change produces fewer clinical events
Randomised cardiovascular eventsThe effect of the tested regimen on a defined clinical endpointWhether results generalise to other populations, doses or endpoints

What the cardiac and vascular experiments contribute

The heart-muscle receptor review compares Chen’s 2011 experiment with Zupcic’s 2024 study. Both investigate cardiomyocyte vitamin D signalling, but they do not produce one uniform phenotype. The earlier model showed enlargement without demonstrated pump failure; the later pressure-overload model showed differences in selected ultrasound measures without greater hypertrophy. Different genetic constructions and stressors matter. This is evidence about receptor-dependent responses in mice, not a human supplementation effect.

The endothelial barrier and vascular-function review separates three measurements. Vila Cuenca’s work found barrier stabilisation with an active vitamin D analogue in kidney-disease rats and cultured human cells. Dreyer’s small kidney-disease trial found a positive stimulated skin-microvascular response, while Borgi’s trial in overweight or obese adults found no significant improvement in brachial-artery dilation. A tighter cell barrier, a local skin response and a large-artery dilation test are related but distinct outcomes.

The smooth-muscle contraction review adds a further distinction. Weishaar’s rat experiment found enhanced arterial contraction after prolonged vitamin D depletion, whereas Jia’s placental-cell experiment found less collagen-gel contraction with calcitriol under its conditions. The latter is a seven-day cultured-cell assay, not an immediate diameter change in an intact human vessel. These results help describe possible mechanisms without establishing that every vitamin D exposure causes uniform vasodilation.

Why associations and inflammatory markers need their own interpretation

Wang’s observational cohort linked lower vitamin D status with later cardiovascular events. Such a pattern can motivate causal research, but health, activity and other characteristics may influence both the blood measurement and future risk. The distinction between correlation and causation remains even after statistical adjustment. The association does not estimate the benefit of assigning supplements.

The inflammation and cardiovascular risk-marker review examines Costenbader’s one-year and Dong’s two: and four-year VITAL analyses. They did not show a consistent reduction across all measured inflammatory markers. Dong found a lower high-sensitivity C-reactive protein (hs-CRP) trajectory at two years but not four years, with additional qualifications about effect magnitude and sensitivity analyses. These are related reports within the same parent trial, not independent clinical replications. They do not demonstrate that an inflammatory-marker change mediated fewer cardiovascular events.

The renin and blood-pressure review provides a direct example of the translation problem. Li’s experiments support receptor-dependent regulation of renin in mice and engineered cells. VitDISH did not clearly lower blood pressure with intermittent cholecalciferol in older people with isolated systolic hypertension. A sound mechanistic observation and a null clinical measurement can coexist when the intervention, model and background physiology differ.

The clinical event trials: a comparison with denominators

A myocardial infarction is a heart attack. Coronary revascularisation is a procedure to restore blood supply, such as a stent or bypass operation. A composite endpoint counts whether a person has any of several specified events. Its exact components matter: VITAL’s primary cardiovascular composite included cardiovascular death, whereas D-Health’s composite included coronary revascularisation. The two rows below therefore describe different clinical definitions.

Trial and tested regimenPopulation and follow-upMain cardiovascular comparison
VITAL: vitamin D3 2,000 IU daily versus placebo25,871 US adults without prior cardiovascular disease; median 5.3 yearsHeart attack, stroke or cardiovascular death: 396/12,927 versus 409/12,944; hazard ratio 0.97, 95% CI 0.85-1.12
D-Health: vitamin D3 60,000 IU monthly versus placebo21,302 analysed Australian adults aged 60-84; median five yearsHeart attack, stroke or coronary revascularisation: 637/10,658 versus 699/10,644; hazard ratio 0.91, 95% CI 0.81-1.01

A hazard ratio compares event rates over follow-up among people still at risk; it is not a percentage-point change in the probability of an event. A ratio of 1 represents no difference. Both main confidence intervals include 1. VITAL’s estimate is close to no difference. D-Health’s estimate favours vitamin D, but the interval remains compatible with no effect. Calling the latter a proven nine-percent reduction would remove an essential part of the result.

VITAL: a large primary-prevention test

Manson and colleagues randomised men aged at least 50 and women aged at least 55 after a placebo run-in. Mean age was 67, about half were women and approximately one fifth of participants reporting race were Black. The factorial design separately assigned vitamin D and omega-3 capsules; the vitamin D analysis accounted for the omega-3 assignment. Physicians unaware of assignment confirmed reported events from records, and the principal analysis retained participants in their assigned groups.

This was not a trial restricted to severe deficiency. Among 15,787 participants with analysable baseline blood samples, mean 25-hydroxyvitamin D was 30.8 ng/mL and 12.7% were below 20 ng/mL. Repeat samples confirmed that the intervention raised concentrations. Average adherence, defined as taking at least two thirds of study capsules, was about 82% with vitamin D and 80% with placebo. Some participants used outside supplements, particularly in the placebo group, which could reduce the contrast between assignments.

The primary cardiovascular result was 0.97 with a 95% confidence interval of 0.85-1.12. Thus the trial did not demonstrate benefit, while its interval does not establish exact equivalence. The expanded composite adding revascularisation was also inconclusive: 0.96, with an interval of 0.86-1.08. Individual heart-attack, stroke and cardiovascular-death estimates did not establish reductions. The trial cannot determine every regimen or the response of people with prolonged, extreme deficiency.

D-Health: a possible signal with important uncertainty

Thompson and colleagues analysed a trial that originally randomised 21,315 people; thirteen were excluded from this analysis because of withdrawn data or incomplete linkage. Unlike VITAL, it did not exclude everyone with previous cardiovascular disease. Mean age was 69 and 54% were men. Events were identified through linked hospital, procedure and mortality records. The trial’s overall primary outcome was all-cause mortality; cardiovascular events were a prespecified tertiary outcome among numerous outcomes, with no adjustment for multiple testing.

The groups showed good separation in vitamin D concentrations during treatment, but baseline concentrations were predicted rather than measured. Approximately 84% and 82% reported taking at least 80% of assigned tablets in the vitamin D and placebo groups. Roughly 80% and 78% were still taking tablets at five years; stopping tablets did not automatically remove participants from linked-outcome follow-up. Missing private-hospital data in two states could undercount some events, although the authors expected little differential undercounting between groups.

The paper’s modelled five-year absolute difference was −5.8 events per 1,000 people, with a 95% confidence interval from −12.2 to +0.5 per 1,000. In ordinary terms, the estimate is about six fewer events per thousand, with uncertainty ranging from about twelve fewer to half an event more. These are standardised cumulative-incidence estimates accounting for competing deaths, not simply the raw percentage difference. The reported number needed to treat of 172 is based on the point estimate; because the interval crosses no effect, it is not a confirmed treatment benefit.

The heart-attack component favoured vitamin D: 194 versus 238 people, hazard ratio 0.81 with a 95% confidence interval of 0.67-0.98. Coronary revascularisation was 0.89 (0.78-1.01), and stroke 0.99 (0.80-1.23). The heart-attack signal deserves attention, but multiple outcomes and the uncertain overall composite prevent presenting it as definitive cardiovascular prevention. Participants can experience more than one component, so adding component counts would overstate the number with any event.

The estimate also looked more favourable among people using non-statin cardiovascular medicines at baseline. However, the interaction test did not establish that their response differed from non-users: P=0.12. A favourable result within one subgroup is not proof of a difference between subgroups. The vitamin D-status subgroup used a prediction model with substantial misclassification, so it cannot establish a reliable concentration target or identify a proven responder group.

What can be concluded across the evidence?

The experiments provide reasons to investigate vitamin D signalling in cardiovascular biology. Observational associations and some positive vascular or biomarker findings add questions worth testing. The event trials provide the more direct evidence for prevention by the tested supplementation regimens. They have not supplied consistent, definitive evidence that those regimens prevent major cardiovascular events across these populations.

The comparison is a structured synthesis of the cited studies, not a new systematic review or pooled meta-analysis. It does not average incompatible endpoints or count related VITAL reports as independent trials. Differences between VITAL and D-Health could reflect chance, populations, endpoint definitions, adherence or dosing; the two trials did not randomise participants between their respective regimens. Their comparison cannot establish which explanation is correct.

For readers moving between the vascular tone pathway and the clinical literature, the key is to preserve the level of the finding. Receptor activity is not the same measurement as a blood concentration, a change in a marker is not an event prevented, and a favourable point estimate is not a benefit established without its uncertainty. This allows the biological findings and the clinical limits to be reported together without promoting or dismissing either.

Scientific sources

Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation. 2011;124(17):1838-1847. DOI: 10.1161/CIRCULATIONAHA.111.032680. PMID: 21947295. The principal experiment; supplementary methods and echocardiography are part of this publication.

Zupcic A, Latic N, Oubounyt M, Ramesova A, Carmeliet G, Baumbach J, Elkjaer ML, Erben RG. Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice. International Journal of Molecular Sciences. 2024;25(11):5929. DOI: 10.3390/ijms25115929. PMID: 38892126. A separate mouse experiment used here to assess the consistency and limits of the earlier findings.

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM. Ergocalciferol and Microcirculatory Function in Chronic Kidney Disease and Concomitant Vitamin D Deficiency: An Exploratory, Double Blind, Randomised Controlled Trial. PLoS ONE. 2014;9(7):e99461. DOI: 10.1371/journal.pone.0099461. PMID: 25006678. Human microcirculatory trial; its supplementary methods and study protocol inform the appraisal.

Borgi L, McMullan C, Wohlhueter A, Curhan GC, Fisher ND, Forman JP. Effect of Vitamin D on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial. American Journal of Hypertension. 2017;30(2):124-129. DOI: 10.1093/ajh/hpw135. PMID: 28077419. Human supplementation comparison.

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.

Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.

Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. Journal of Clinical Investigation. 1987;79(6):1706-1712. DOI: 10.1172/JCI113010. PMID: 3034981. Full-paper appraisal focused on the vascular experiment; the separate cardiac calcium-rescue experiment is distinguished.

Jia X, Gu Y, Groome LJ, Al-Kofahi M, Alexander JS, Li W, Wang Y. 1,25(OH)2D3 Induces Placental Vascular Smooth Muscle Cell Relaxation by Phosphorylation of Myosin Phosphatase Target Subunit 1Ser507: Potential Beneficial Effects of Vitamin D on Placental Vasculature in Humans. Biology of Reproduction. 2016;94(5):116, 1-8. DOI: 10.1095/biolreprod.116.138362. PMID: 27075619. Cultured human placental smooth-muscle experiment.

Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation. 2002;110(2):229-238. DOI: 10.1172/JCI15219. PMID: 12122115. Mouse and cell experiments; complete main paper, tables and figures examined.

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

Manson JE, Cook NR, Lee IM, and colleagues; VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine. 2019;380(1):33-44. DOI: 10.1056/NEJMoa1809944. PMID: 30415629. Main clinical event report from VITAL. This appraisal uses the complete main paper; its supplementary appendix was not accessible for independent inspection.

Thompson B, Waterhouse M, English DR, and colleagues. Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. 2023;381:e075230. DOI: 10.1136/bmj-2023-075230. PMID: 37380191. Cardiovascular analysis of D-Health, including its supplementary methods and results.

Related reading

Original sources

Source

Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy

Published in Circulation (2011).

Publication details

Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation. 2011;124(17):1838-1847. DOI: 10.1161/CIRCULATIONAHA.111.032680. PMID: 21947295. The principal experiment; supplementary methods and echocardiography are part of this publication.

Read more →
Source

Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice

This study aimed to further elucidate the role of vitamin D signaling in the development of left ventricular (LV) hypertrophy and dysfunction.

Publication details

Zupcic A, Latic N, Oubounyt M, Ramesova A, Carmeliet G, Baumbach J, Elkjaer ML, Erben RG. Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice. International Journal of Molecular Sciences. 2024;25(11):5929. DOI: 10.3390/ijms25115929. PMID: 38892126. A separate mouse experiment used here to assess the consistency and limits of the earlier findings.

Read more →
Source

Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability

Published in Journal of the American Heart Association (2018).

Publication details

Vila Cuenca M, Ferrantelli E, Meinster E, Pouw SM, Kovačević I, de Menezes RX, Niessen HW, Beelen RHJ, Hordijk PL, Vervloet MG. Vitamin D Attenuates Endothelial Dysfunction in Uremic Rats and Maintains Human Endothelial Stability. Journal of the American Heart Association. 2018;7(17):e008776. DOI: 10.1161/JAHA.118.008776. PMID: 30371149. Principal barrier experiment, including supplementary kidney-function and α-Klotho results.

Read more →
Source

Erratum

Published in American Journal of Hypertension (2017).

Publication details

Correction to Borgi and colleagues: Erratum. American Journal of Hypertension. 2017;30(7):731. DOI: 10.1093/ajh/hpx030. PMID: 28472334. Replaces Figure 3; the numerical comparison discussed here is reported in the article text.

Read more →
Source

Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial

Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.

Publication details

Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.

Read more →
Source

Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults

Published in Clinical Chemistry (2019).

Publication details

Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.

Read more →
Source

Vitamin D Deficiency and Risk of Cardiovascular Disease

Published in Circulation (2008).

Publication details

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.

Read more →
Source

Vitamin D3 and cardiovascular function in rats

Published in Journal of Clinical Investigation (1987).

Publication details

Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. Journal of Clinical Investigation. 1987;79(6):1706-1712. DOI: 10.1172/JCI113010. PMID: 3034981. Full-paper appraisal focused on the vascular experiment; the separate cardiac calcium-rescue experiment is distinguished.

Read more →
Source

1,25(OH)2D3 Induces Placental Vascular Smooth Muscle Cell Relaxation by Phosphorylation of Myosin Phosphatase Target Subunit 1Ser507: Potential Beneficial Effects of Vitamin D on Placental Vasculature in Humans

Published in Biology of Reproduction (2016).

Publication details

Jia X, Gu Y, Groome LJ, Al-Kofahi M, Alexander JS, Li W, Wang Y. 1,25(OH)2D3 Induces Placental Vascular Smooth Muscle Cell Relaxation by Phosphorylation of Myosin Phosphatase Target Subunit 1Ser507: Potential Beneficial Effects of Vitamin D on Placental Vasculature in Humans. Biology of Reproduction. 2016;94(5):116, 1-8. DOI: 10.1095/biolreprod.116.138362. PMID: 27075619. Cultured human placental smooth-muscle experiment.

Read more →
Source

Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial

Published in JAMA Internal Medicine (2013).

Publication details

Witham MD, Price RJG, Struthers AD, Donnan PT, Messow CM, Ford I, McMurdo MET. Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension: The VitDISH Randomized Controlled Trial. JAMA Internal Medicine. 2013;173(18):1672-1679. DOI: 10.1001/jamainternmed.2013.9043. PMID: 23939263. Randomised clinical trial; main paper, figures and tables examined. Supplementary eMethods and adverse-event eTable were not accessible.

Read more →
Source

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Published in New England Journal of Medicine (2019).

Publication details

Manson JE, Cook NR, Lee IM, and colleagues; VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine. 2019;380(1):33-44. DOI: 10.1056/NEJMoa1809944. PMID: 30415629. Main clinical event report from VITAL. This appraisal uses the complete main paper; its supplementary appendix was not accessible for independent inspection.

Read more →